GlassScriptPhysician profile
Chandra S Ghosh
NPI 1578515060
$2,630.73
in general payments reported to CMS, 2019-2025
37 companies · $670 in 2025
The $670 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $149 · 2021: $196 · 2022: $324 · 2023: $597 · 2024: $355 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.02 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $315.23 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $199.74 | 2019-2025 | Repatha, Evenity |
| Abbott Laboratories | $194.87 | 2022-2025 | Freestyle Libre 3 |
| Abbvie INC. | $191.95 | 2020-2024 | |
| Intra-Sana Laboratories | $164.24 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Mannkind Corporation | $138.27 | 2019-2024 | Afrezza |
| Lilly USA, LLC | $135.37 | 2020-2025 | Mounjaro, Jardiance |
| Pfizer INC. | $113.96 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $113.51 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $111.95 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Corcept Therapeutics | $111.69 | 2021 | |
| Glaxosmithkline, LLC. | $80.57 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Beta Bionics, INC. | $77.30 | 2023-2024 | Ilet Bionic Pancreas |
| Astellas Pharma US INC | $71.43 | 2023-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $70.96 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $48.98 | 2023-2025 | Gvoke Hypopen |
| Ucb, INC. | $45.39 | 2025 | Zilbrysq |
| Dexcom, INC. | $38.92 | 2022 | |
| Boston Scientific Corporation | $38.75 | 2025 | General - Pain Management |
| Amarin Pharma, INC. | $37.94 | 2019-2020 | |
| Dynavax Technologies Corporation | $35.06 | 2023-2025 | Heplisav-B |
| Teva Pharmaceuticals USA, INC. | $29.62 | 2019-2022 | |
| Radius Health, INC. | $26.30 | 2023 | Tymlos |
| Janssen Pharmaceuticals, INC | $26.26 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $24.76 | 2023 | |
| Alkermes, INC. | $24.07 | 2019 | |
| Ibsa Pharma INC. | $21.74 | 2024 | Licart, Tirosint |
| Amneal Pharmaceuticals LLC | $19.08 | 2019 | |
| Ascendis Pharma Endocrinology INC | $17.58 | 2025 | Yorvipath |
| Viiv Healthcare Company | $16.14 | 2022 | |
| Cequr Corporation | $16.03 | 2023 | Cequr Simplicity |
| Mylan Specialty L.P. | $16.01 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $15.08 | 2021 | |
| Gilead Sciences, INC. | $15.02 | 2019 | |
| Acadia Pharmaceuticals INC | $14.08 | 2024 | Nuplazid |
| Alnylam Pharmaceuticals INC. | $12.88 | 2023 | Onpattro |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Ghosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.